Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07107152 · ClinicalTrials.gov registry record · NA
Effect of Static vs. Conversational AI-Generated Messages on Colorectal Cancer Screening Intent: a Randomized Controlled Trial
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 915
- Enrollment target
NCT07107152: Completed NA study, sponsored by University of Pennsylvania.
NCT07107152 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 915 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07107152, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 915 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess whether messages generated by a large language model (LLM), including both static and conversational formats, can increase colorectal cancer (CRC) screening intentions among U.S. adults aged 45-75 who have never completed CRC screening. The main questions it aims to answer are: Do personalized, AI-generated messages increase the self-reported likelihood of completing a stool-based CRC screening test within 12 months? Do they also increase intent to undergo colonoscopy screening within 12 months? Researchers will compare four groups: (1) no message control, (2) expert-written patient education materials, (3) a single AI-generated persuasive message, and (4) a motivational interviewing-style AI chatbot. These comparisons will help assess whether a conversational format offers added benefit over static AI or expert-generated content. Participants will: Be randomly assigned to one of the four study arms Spend at least 3 minutes reading or interacting with their assigned material Complete pre- and post-intervention surveys assessing intent to receive CRC screening Receive messages tailored to their self-reported demographics, including age, political ideology, gender, education, community setting (urban, rural, suburb), self-reported health, and the last time they saw their PCP
Primary Outcome
Measured on a 0-100 scale, where 0 = "Extremely unlikely" and 100 = "Extremely likely." Assessed before and after the intervention. Change in score indicates difference in participant intention to complete a stool-based CRC screening test.
Interventions
- BEHAVIORAL single GPT generated message
- BEHAVIORAL AI Chatbot
- BEHAVIORAL Expert-Written Patient Materials
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 915 participants |
| Start Date | 2025-06-11 |
| Est. Completion | 2025-06-21 |
| Phase | NA |
What the finished NCT07107152 record still lists
NCT07107152 is an interventional study that assigns participants to a tested intervention. The registered 915 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 3 interventions - of which single GPT generated message is the first listed.
NCT07107152 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07107152 about?
NCT07107152 is a clinical study titled "Effect of Static vs. Conversational AI-Generated Messages on Colorectal Cancer Screening Intent: a Randomized Controlled Trial". The goal of this clinical trial is to assess whether messages generated by a large language model (LLM), including both static and conversational formats, can increase colorectal cancer (CRC) screening intentions among U.S. adults aged 45-75 who have never completed CRC screening. The main questions...
What is the current status of trial NCT07107152?
This trial is currently completed. It is a NA study. The enrollment target is 915 participants. The study started on 2025-06-11. Estimated completion is 2025-06-21.
What interventions are being tested in trial NCT07107152?
The interventions under investigation include: single GPT generated message (BEHAVIORAL), AI Chatbot (BEHAVIORAL), Expert-Written Patient Materials (BEHAVIORAL).
Who is sponsoring clinical trial NCT07107152?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07107152's enrollment target sits among peer trials
915 124th of 2000 higher than 1,877 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI